<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

• Rami Komrokji,
• Najla al Ali,
• Onyee Chan,
• Kendra Sweet,
• Andrew Kuykendall,
• Jeffrey Lancet,
• Eric Padron,
• David A. Sallman

Affiliations

Rami Komrokji

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Najla al Ali

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Onyee Chan

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Kendra Sweet

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Andrew Kuykendall

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Jeffrey Lancet

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

Eric Padron

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl

David A. Sallman

Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, Fl